Evaluation of porfimer sodium in dogs and cats with spontaneous tumors

Veterinary Therapeutics

Volumn 5, Issue 1, 2004, Pages

  Gloi, Aime ^a   Beck, Elsa ^a   Bentz, Amy ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANIS FAMILIARIS;

EID: 79251472440     PISSN: 15283593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Fisher AMR, Murphree AL, Gomer CJ: Clinical and preclinical photodynamic therapy. Lasers Surg Med 17: 2-31, 1996.
2. Gomer CJ, Dougherty TJ: Determination of [3H]- and [14C]hematoporphyrin derivatives distribution in malignant and normal tissue. Cancer Res 39:146-151, 1979.
3. Frazier DL, Milligan JA, Morgan AR, Overholt BF: Canine treatment with SnET2 for photodynamic therapy. SPIE 1203:196-201, 1990.
4. Ronn AM, Batti J, Lee CJ, et al: Comparative biodistribution of meta-Tetra (Hydroxyphenyl) chlorin in multiple species: Clinical implications for photodynamic therapy. Laser Surg Med 20:437-442, 1997.
5. Giulio J: Tumour photosensitizers: Approaches to enhance the selectivity and efficiency of photodynamic therapy. Photochem Photobiol B 36:87-93, 1996.
6. Ho Y-K, Missert JR, Dougherty TJ: Activity and physicochemical properties of Photofrin. Photochem Photobiol 54:83-87, 1991.
7. Dougherty TJ, Cooper MT, Mang TS: Cutaneous phototoxicity occurrences in patients receiving Photofrin. Lasers Med Surg 10:485-488, 1990.
8. Brodey RS: The use of naturally occurring cancer in domestic animals for research into human: General considerations and review of canine skeletal osteosarcoma. Yale J Bio Med 52:345-361, 1979.
9. Cotchin E: Comparative oncology: The veterinary contribution. Proc Royal Soc Med 69:17-24, 1976.
10. Gilette EL: Spontaneous neoplasm as models for therapeutics agents, in Fidler IJ, White RJ (eds): Design of Models for Testing Cancer Therapeutic Agents. New York, Van Nostrand Reinhold, 1982, pp 185-192.
11. Ferracini R, Angelini P, Caghero E: MET oncogene aberrant expression in canine osteosarcoma. J Orthop Res 18(2):253-236, 2000.
12. Brown S, Vernon DI, Holroy JA, et al: Pharmacokinetics of Photofrin in man, in Spinelli R, Dal Fante M, Marchessini R (eds): Photodynamic Therapy and Biomedical Lasers. Amsterdam, Elsevier, 1992, pp 475-479.
13. Johnson RE, Cameron TP, Kinard R: Canine lymphoma as a potential model for experimental therapeutics. Cancer Res 28:2562-2564, 1968.
14. Misdorp W, Hart AA: Prognostic factors in canine mammary cancer. J Nat Cancer Inst 56:779-786, 1976.
15. Greenberg H: Mathematical Programming Glossary. Available at: http://carbon.cudenver.edu/̃hgreenbe/glossary/second.php?page=F.html; accessed August 2003.
16. Buyse M, Staquet M, Sylvester R (eds): Cancer Clinical Trial Methods and Practice. New York, Oxford University Press, 1984.
17. Lilge L, O'Carrol C, Wilson BC: Solubilization technique for photosensitizer quantification in ex-vivo tissue samples. J Photochem Photobiol B 65(4):701-706, 1997.
18. Gloi AM, Beck E: Biodistribution of three photosensitizers in dogs with spontaneous tumors. Vet Ther 4(2):155-165, 2003.
19. Bellinier DA, Ho Y-K, Pandley RK, et al: Distribution and elimination of Photofrin II in mice. J Photochem Photobiol B 50:221-228, 1989.
20. Bugelski PJ, Dougherty TJ: Autoradiographic of HPD in normal and tumor tissue of the mouse. Cancer Res 41:4606-4612, 1981.
21. Pogue W, Momma T, Wu H, Hasan T: Transient absorption in vivo during photodynamic therapy with pulsed laser light. Br J Cancer 80(3-4):344-351, 1999.